Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer
Ontology highlight
ABSTRACT: Primary ObjectiveTo assess a maximal tolerable dose of a chemotherapy-combination of Cetuximab, Irinotecan, Oxaliplatin and 5-FU/ Folinic acid as first-line treatment for metastatic colorectal cancer.
Primary endpoints: To assess a maximal tolerable dose of a chemotherapy-combination of Cetuximab, Irinotecan, Oxaliplatin and 5-FU/ Folinic acid as first-line treatment for metastatic colorectal cancer.
DISEASE(S): First-line Treatment Of Metastatic Colorectal Cancer
PROVIDER: 2520357 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA